Ask AI
ProCE Banner Activity

ACTG A5391/DO-IT: Metabolic Parameters and Body Composition After Switch to DOR ± TDF vs Continuing INSTI + TAF/FTC 

Conference Coverage
Slideset

In the ACTG A5391/DO-IT trial of people with obesity receiving INSTI plus TAF/FTC, switching to doravirine with or without switching from TAF/FTC to TDF/FTC did not result in significant change in fasting lipids or insulin resistance at 48 weeks vs continuing the baseline INSTI regimen.

Released: October 23, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare